Tags

Type your tag names separated by a space and hit enter

Quantitative in vivo biomarkers of oxidative damage and their application to the diagnosis and management of Alzheimer's disease.

Abstract

Dementia from Alzheimer's disease (AD) represents a significant and growing public health burden and presents a clear therapeutic imperative. Key to success in this undertaking will be biomarkers for the objective assessment of disease progression and response to therapeutics. Oxidative damage is one facet of AD pathogenesis for which there are experimentally validated quantitative in vivo biomarkers, the F2-isoprostanes (IsoPs). While plasma- or urine-based assays are desirable, consistent and reproducible cross-sectional data for increased F2-IsoPs in AD and mild cognitive impairment have been obtained only for CSF. In addition, measurement of CSF F2-IsoPs can increase the accuracy of laboratory-based classification of geriatric dementias, and have been used to assess objectively the response to anti-oxidant interventions in AD.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Pathology, University of Washington, Seattle, WA 98104, USA. tmontine@u.washington.edu

    , , ,

    Source

    MeSH

    Alzheimer Disease
    Apolipoproteins E
    Biomarkers
    Brain
    Cognition Disorders
    Dementia
    F2-Isoprostanes
    Humans
    Oxidative Stress
    Risk Factors

    Pub Type(s)

    Journal Article
    Review

    Language

    eng

    PubMed ID

    16556967

    Citation

    Montine, Thomas J., et al. "Quantitative in Vivo Biomarkers of Oxidative Damage and Their Application to the Diagnosis and Management of Alzheimer's Disease." Journal of Alzheimer's Disease : JAD, vol. 8, no. 4, 2005, pp. 359-67.
    Montine TJ, Quinn JF, Montine KS, et al. Quantitative in vivo biomarkers of oxidative damage and their application to the diagnosis and management of Alzheimer's disease. J Alzheimers Dis. 2005;8(4):359-67.
    Montine, T. J., Quinn, J. F., Montine, K. S., Kaye, J. A., & Breitner, J. C. (2005). Quantitative in vivo biomarkers of oxidative damage and their application to the diagnosis and management of Alzheimer's disease. Journal of Alzheimer's Disease : JAD, 8(4), pp. 359-67.
    Montine TJ, et al. Quantitative in Vivo Biomarkers of Oxidative Damage and Their Application to the Diagnosis and Management of Alzheimer's Disease. J Alzheimers Dis. 2005;8(4):359-67. PubMed PMID: 16556967.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Quantitative in vivo biomarkers of oxidative damage and their application to the diagnosis and management of Alzheimer's disease. AU - Montine,Thomas J, AU - Quinn,Joseph F, AU - Montine,Kathleen S, AU - Kaye,Jeffrey A, AU - Breitner,John C S, PY - 2006/3/25/pubmed PY - 2006/10/13/medline PY - 2006/3/25/entrez SP - 359 EP - 67 JF - Journal of Alzheimer's disease : JAD JO - J. Alzheimers Dis. VL - 8 IS - 4 N2 - Dementia from Alzheimer's disease (AD) represents a significant and growing public health burden and presents a clear therapeutic imperative. Key to success in this undertaking will be biomarkers for the objective assessment of disease progression and response to therapeutics. Oxidative damage is one facet of AD pathogenesis for which there are experimentally validated quantitative in vivo biomarkers, the F2-isoprostanes (IsoPs). While plasma- or urine-based assays are desirable, consistent and reproducible cross-sectional data for increased F2-IsoPs in AD and mild cognitive impairment have been obtained only for CSF. In addition, measurement of CSF F2-IsoPs can increase the accuracy of laboratory-based classification of geriatric dementias, and have been used to assess objectively the response to anti-oxidant interventions in AD. SN - 1387-2877 UR - https://www.unboundmedicine.com/medline/citation/16556967/Quantitative_in_vivo_biomarkers_of_oxidative_damage_and_their_application_to_the_diagnosis_and_management_of_Alzheimer's_disease_ L2 - https://content.iospress.com/openurl?genre=article&issn=1387-2877&volume=8&issue=4&spage=359 DB - PRIME DP - Unbound Medicine ER -